{"id":"NCT00441012","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)","officialTitle":"A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2007-02-27","resultsPosted":"2009-07-10","lastUpdate":"2015-03-19"},"enrollment":546,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type B","Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: Modified Process Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: COMVAX™","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"To determine if there is an improvement in the immune response to HBsAg (hepatitis B virus) in healthy infants using a modified process in a combination Haemophilus Influenzae, type b/Hepatitis B vaccine and a currently licensed Haemophilus Influenzae, type b/Hepatitis B vaccine","primaryOutcome":{"measure":"The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose.","timeFrame":"11 months (1 month after the third dose)","effectByArm":[{"arm":"Modified Process Vaccine","deltaMin":230,"sd":null},{"arm":"COMVAX™","deltaMin":226,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"40 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21875633"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Injection site pain","Injection site erythema","Pyrexia","Injection site swelling","Irritability"]}}